Company profile

ChemoCentryx is a leading late stage biotech company producing oral drugs for treating auto-immune diseases, inflammatory disorders and cancer. It is a pioneer in research into the chemokine network (network of signal substances) that plays a crucial role in regulating the immune system. Crohn’s disease, rheumatoid arthritis and multiple sclerosis are some of the diseases which ChemoCentryx has programmes to combat. In 2006 it concluded a cooperation agreement with GlaxoSmithKline for its Traficet-EN treatment of irritable bowel syndrome. ChemoCentryx went public on the Nasdaq in February 2012.

ChemoCentryx
  • Activity: Research into the chemokine network
  • Website: www.chemocentryx.com
  • Location: United States
  • Entry: 2004
  • Platform: Health & Care